Extranodal extension of lymph node metastasis influences recurrence in prostate cancer

A systematic review and meta-Analysis

Claudio Luchini, Achim Fleischmann, Joost L. Boormans, Matteo Fassan, Alessia Nottegar, Paola Lucato, Brendon Stubbs, Marco Solmi, Antonio Porcaro, Nicola Veronese, Matteo Brunelli, Aldo Scarpa, Liang Cheng

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The extranodal extension (ENE) of nodal metastasis involves the extension of neoplastic cells through the lymph node capsule into the perinodal adipose tissue. This morphological feature has recently been indicated as an important prognostic factor in various cancer types, but its role in prostate cancer is still unclear. We aimed to clarify it, performing the first meta-Analysis on this issue, comparing prognostic parameters in surgically treated, node-positive prostate cancer patients with (ENE+) vs. without (ENE-) ENE. Data were summarized using risk ratios (RRs) for number of deaths/recurrences and hazard ratios (HRs), with 95% confidence intervals (CI), for the time-dependent risk related to ENE positivity. Six studies followed-up 1,113 patients with N1 prostate cancer (658 ENE+ vs. 455 ENE-) for a median of 83 months. The presence of ENE was associated with a significantly higher risk of biochemical recurrence (RR = 1.15; 95%CI: 1.03-1.28; I2 = 0%; HR = 1.40, 95%CI: 1.12-1.74; I2 = 0%) and "global" (biochemical recurrence and distant metastasis) recurrence (RR = 1.15; 95%CI: 1.04-1.28; I2 = 0%; HR = 1.41, 95%CI: 1.14-1.74; I2 = 0%). ENE emerged as a potential prognostic moderator, earmarking a subgroup of patients at higher risk of recurrence. It may be considered for the prognostic stratification of metastatic patients. New possible therapeutic approaches may explore more in depth this prognostic parameter.

Original languageEnglish (US)
Article number2374
JournalScientific Reports
Volume7
Issue number1
DOIs
StatePublished - Dec 1 2017

Fingerprint

Meta-Analysis
Prostatic Neoplasms
Lymph Nodes
Confidence Intervals
Neoplasm Metastasis
Recurrence
Odds Ratio
Capsules
Adipose Tissue
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Extranodal extension of lymph node metastasis influences recurrence in prostate cancer : A systematic review and meta-Analysis. / Luchini, Claudio; Fleischmann, Achim; Boormans, Joost L.; Fassan, Matteo; Nottegar, Alessia; Lucato, Paola; Stubbs, Brendon; Solmi, Marco; Porcaro, Antonio; Veronese, Nicola; Brunelli, Matteo; Scarpa, Aldo; Cheng, Liang.

In: Scientific Reports, Vol. 7, No. 1, 2374, 01.12.2017.

Research output: Contribution to journalArticle

Luchini, C, Fleischmann, A, Boormans, JL, Fassan, M, Nottegar, A, Lucato, P, Stubbs, B, Solmi, M, Porcaro, A, Veronese, N, Brunelli, M, Scarpa, A & Cheng, L 2017, 'Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: A systematic review and meta-Analysis', Scientific Reports, vol. 7, no. 1, 2374. https://doi.org/10.1038/s41598-017-02577-4
Luchini, Claudio ; Fleischmann, Achim ; Boormans, Joost L. ; Fassan, Matteo ; Nottegar, Alessia ; Lucato, Paola ; Stubbs, Brendon ; Solmi, Marco ; Porcaro, Antonio ; Veronese, Nicola ; Brunelli, Matteo ; Scarpa, Aldo ; Cheng, Liang. / Extranodal extension of lymph node metastasis influences recurrence in prostate cancer : A systematic review and meta-Analysis. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{4b2815f97c1f463d9b3ef473b17c7902,
title = "Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: A systematic review and meta-Analysis",
abstract = "The extranodal extension (ENE) of nodal metastasis involves the extension of neoplastic cells through the lymph node capsule into the perinodal adipose tissue. This morphological feature has recently been indicated as an important prognostic factor in various cancer types, but its role in prostate cancer is still unclear. We aimed to clarify it, performing the first meta-Analysis on this issue, comparing prognostic parameters in surgically treated, node-positive prostate cancer patients with (ENE+) vs. without (ENE-) ENE. Data were summarized using risk ratios (RRs) for number of deaths/recurrences and hazard ratios (HRs), with 95{\%} confidence intervals (CI), for the time-dependent risk related to ENE positivity. Six studies followed-up 1,113 patients with N1 prostate cancer (658 ENE+ vs. 455 ENE-) for a median of 83 months. The presence of ENE was associated with a significantly higher risk of biochemical recurrence (RR = 1.15; 95{\%}CI: 1.03-1.28; I2 = 0{\%}; HR = 1.40, 95{\%}CI: 1.12-1.74; I2 = 0{\%}) and {"}global{"} (biochemical recurrence and distant metastasis) recurrence (RR = 1.15; 95{\%}CI: 1.04-1.28; I2 = 0{\%}; HR = 1.41, 95{\%}CI: 1.14-1.74; I2 = 0{\%}). ENE emerged as a potential prognostic moderator, earmarking a subgroup of patients at higher risk of recurrence. It may be considered for the prognostic stratification of metastatic patients. New possible therapeutic approaches may explore more in depth this prognostic parameter.",
author = "Claudio Luchini and Achim Fleischmann and Boormans, {Joost L.} and Matteo Fassan and Alessia Nottegar and Paola Lucato and Brendon Stubbs and Marco Solmi and Antonio Porcaro and Nicola Veronese and Matteo Brunelli and Aldo Scarpa and Liang Cheng",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-02577-4",
language = "English (US)",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Extranodal extension of lymph node metastasis influences recurrence in prostate cancer

T2 - A systematic review and meta-Analysis

AU - Luchini, Claudio

AU - Fleischmann, Achim

AU - Boormans, Joost L.

AU - Fassan, Matteo

AU - Nottegar, Alessia

AU - Lucato, Paola

AU - Stubbs, Brendon

AU - Solmi, Marco

AU - Porcaro, Antonio

AU - Veronese, Nicola

AU - Brunelli, Matteo

AU - Scarpa, Aldo

AU - Cheng, Liang

PY - 2017/12/1

Y1 - 2017/12/1

N2 - The extranodal extension (ENE) of nodal metastasis involves the extension of neoplastic cells through the lymph node capsule into the perinodal adipose tissue. This morphological feature has recently been indicated as an important prognostic factor in various cancer types, but its role in prostate cancer is still unclear. We aimed to clarify it, performing the first meta-Analysis on this issue, comparing prognostic parameters in surgically treated, node-positive prostate cancer patients with (ENE+) vs. without (ENE-) ENE. Data were summarized using risk ratios (RRs) for number of deaths/recurrences and hazard ratios (HRs), with 95% confidence intervals (CI), for the time-dependent risk related to ENE positivity. Six studies followed-up 1,113 patients with N1 prostate cancer (658 ENE+ vs. 455 ENE-) for a median of 83 months. The presence of ENE was associated with a significantly higher risk of biochemical recurrence (RR = 1.15; 95%CI: 1.03-1.28; I2 = 0%; HR = 1.40, 95%CI: 1.12-1.74; I2 = 0%) and "global" (biochemical recurrence and distant metastasis) recurrence (RR = 1.15; 95%CI: 1.04-1.28; I2 = 0%; HR = 1.41, 95%CI: 1.14-1.74; I2 = 0%). ENE emerged as a potential prognostic moderator, earmarking a subgroup of patients at higher risk of recurrence. It may be considered for the prognostic stratification of metastatic patients. New possible therapeutic approaches may explore more in depth this prognostic parameter.

AB - The extranodal extension (ENE) of nodal metastasis involves the extension of neoplastic cells through the lymph node capsule into the perinodal adipose tissue. This morphological feature has recently been indicated as an important prognostic factor in various cancer types, but its role in prostate cancer is still unclear. We aimed to clarify it, performing the first meta-Analysis on this issue, comparing prognostic parameters in surgically treated, node-positive prostate cancer patients with (ENE+) vs. without (ENE-) ENE. Data were summarized using risk ratios (RRs) for number of deaths/recurrences and hazard ratios (HRs), with 95% confidence intervals (CI), for the time-dependent risk related to ENE positivity. Six studies followed-up 1,113 patients with N1 prostate cancer (658 ENE+ vs. 455 ENE-) for a median of 83 months. The presence of ENE was associated with a significantly higher risk of biochemical recurrence (RR = 1.15; 95%CI: 1.03-1.28; I2 = 0%; HR = 1.40, 95%CI: 1.12-1.74; I2 = 0%) and "global" (biochemical recurrence and distant metastasis) recurrence (RR = 1.15; 95%CI: 1.04-1.28; I2 = 0%; HR = 1.41, 95%CI: 1.14-1.74; I2 = 0%). ENE emerged as a potential prognostic moderator, earmarking a subgroup of patients at higher risk of recurrence. It may be considered for the prognostic stratification of metastatic patients. New possible therapeutic approaches may explore more in depth this prognostic parameter.

UR - http://www.scopus.com/inward/record.url?scp=85019903122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019903122&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-02577-4

DO - 10.1038/s41598-017-02577-4

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 2374

ER -